Skip to content
Disclosery

Foresite Capital Management IV, LLC

Follow

13F filer, CIK 1704132, WEST HOLLYWOOD, CA

Foresite Capital Management IV, LLC reported $237,082,221 across 8 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-062462

Period
2026-03-31
Reported value
$237M
Holdings
8
Top 10 weight
100%
New
1
Sold out
0

Part of the filer group Foresite Capital Management VI LLC

How groups are built

Stakes and trades reported after 2026-03-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • IRLA QUINCE THERAPEUTICS INC: 13G 652,039 shares, 6% of the class, 13G filed 2026-10-14, 0001104659-26-115859Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
EIKNnew+1,943,682$20.6M
CYTKadded+45,000$2.97M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MAZEreduced-365,756-$10.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001104659-26-062462, largest first. % of portfolio is the value over $237,082,221, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,397,881 shares; 2024Q4: 4,397,881 shares; 2025Q1: 4,410,581 shares; 2025Q2: 4,410,581 shares; 2025Q3: 4,778,581 shares; 2025Q4: 4,778,581 shares; 2026Q1: 4,778,581 shares 4,778,581$135M56.94%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 458,295 shares; 2025Q4: 458,295 shares; 2026Q1: 503,295 shares 503,295$33.2M13.99%+45,000Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,943,682 shares 1,943,682$20.6M8.67%newTimeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 800,399 shares; 2025Q3: 800,399 shares; 2025Q4: 800,399 shares; 2026Q1: 800,399 shares 800,399$16.1M6.77%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,000,000 shares; 2024Q4: 1,000,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares 1,000,000$9.95M4.2%0Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares 160,000$9.3M3.92%0Timeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,887,200 shares; 2026Q1: 3,887,200 shares 3,887,200$8.36M3.53%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 2,111,919 shares; 2025Q2: 2,111,919 shares; 2025Q3: 522,657 shares; 2025Q4: 522,657 shares; 2026Q1: 156,901 shares 156,901$4.68M1.98%-365,756Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-062462 base2026-05-15acceptance time not in the bulk data set